Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leiomyoma 3Inflammation 2Frailty 2Small Cell Lung Carcinoma 1Radiodermatitis 1Prostatic Neoplasms 1Papillomavirus Infections 1Low-Grade Intraepithelial Neoplasia of Cervix 1Liver Neoplasms 1Liver Cirrhosis 1Fibrosis 1Esophageal Neoplasms 1Deglutition Disorders 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 109Radiotherapy 100Fluorouracil 90Paclitaxel 75Oxaliplatin 63Docetaxel 56Carboplatin 55Irinotecan 41Esophagectomy 41Leucovorin 40Capecitabine 39Surgical Procedures, Operative 36Radiation 36Drug Therapy 31Neoadjuvant Therapy 25Chemoradiotherapy 18Cetuximab 18S 1 (combination) 17pembrolizumab 16camrelizumab 16Nivolumab 15Magnetic Resonance Spectroscopy 15Bevacizumab 15Blood Specimen Collection 14Surveys and Questionnaires 12Radiotherapy, Intensity-Modulated 12Immunotherapy 11Epirubicin 11Biopsy 11Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Neoplasms × epigallocatechin gallate × Clear all
NCT06398405 2024-05-03

A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

Shandong Cancer Hospital and Institute

Phase 2 Unknown
72 enrolled
Gastrointestinal

Deglutition Disorders, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡